Interventional firm Guidant has completed patient enrollment in its second clinical trial designed to evaluate carotid artery stenting as a minimally invasive alternative for patients who are ineligible for current surgical options or at high surgical risk.
The clinical trial, called ARCHeR RX (Acculink for Revascularization of Carotids in High-Risk Patients), is a prospective, non-randomized, multi-center, single-arm study that enrolled a total of 145 patients in the U.S., Germany, The Netherlands, Belgium, and Argentina. The trial utilizes the firm’s next-generation embolic protection device, the RX Accunet, and a rapid exchange stent system, the RX Acculink carotid stent. The first patient was treated in late May 2003, according to the Indianapolis-based company.
By AuntMinnie.com staff writersSeptember 24, 2003
Related Reading
Guidant acquires bioabsorbable polymers, September 2, 2003
Guidant records strong sales, posts loss in Q2, July 17, 2003
Guidant and OIG reach agreement, July 1, 2003
Guidant to stop selling aortic aneurysm device, close unit, June 17, 2003
Guidant admits to hiding defects in endovascular aneurysm-repair system, June 13, 2003
Copyright © 2003 AuntMinnie.com
